Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
52.95
-0.23 (-0.43%)
At close: Jun 27, 2025, 4:00 PM
54.00
+1.05 (1.98%)
After-hours: Jun 27, 2025, 6:20 PM EDT
Merus Revenue
Merus had revenue of $26.49M in the quarter ending March 31, 2025, with 235.76% growth. This brings the company's revenue in the last twelve months to $54.73M, up 42.77% year-over-year. In the year 2024, Merus had annual revenue of $36.13M, down -17.78%.
Revenue (ttm)
$54.73M
Revenue Growth
+42.77%
P/S Ratio
64.82
Revenue / Employee
$170,505
Employees
321
Market Cap
3.95B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36.13M | -7.81M | -17.78% |
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MRUS News
- 18 days ago - Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus - Seeking Alpha
- 25 days ago - Merus N.V. Announces Pricing of Public Offering of Common Shares - GlobeNewsWire
- 26 days ago - Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 4 weeks ago - Merus to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC - GlobeNewsWire
- 6 weeks ago - Merus Announces the Journal Publication of Petosemtamab Mechanism of Action - GlobeNewsWire
- 7 weeks ago - Merus to Present at BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 7 weeks ago - Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - GlobeNewsWire